Related Experiment Video
Updated: Jun 28, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
Published on: June 12, 2021
Regulatory role of CD39 and CD73 in tumor immunity
Nicole Kaplinsky1, Kada Williams1, Dean Watkins1
1University of Toledo College of Medicine, Toledo, OH 43614, USA.
Abstract:
CD39 is the rate-limiting enzyme for the molecular signal cascade leading to the generation of ADP and adenosine monophosphate (AMP). In conjunction with CD73, CD39 converts adenosine triphosphate (ATP) to ADP and AMP, which leads to the accumulation of immunosuppressive adenosine in the tumor microenvironment. This review focuses on the role of CD39 and CD73 in immune response and malignant progression, including the expression of CD39 within the tumor microenvironment and its relationship to immune effector cells, and its role in antigen presentation. The role of CD39- and CD73-targeting therapeutics and cancer-directed clinical trials investigating CD39 modulation are also explored.
Related Concept Videos
The Tumor Microenvironment
Tumor Immunotherapy
Abnormal Proliferation
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Mitogens and the Cell Cycle
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...

